PriceTargets.com logo

Anixa Biosciences - ANIX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.50
  • Forecasted Upside: 140.83%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.36 As of 03/24/2023 01:00 AM ET
▲ +0.05 (1.16%)

This chart shows the closing price for ANIX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Anixa Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANIX

Analyst Price Target is $10.50
▲ +140.83% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Anixa Biosciences in the last 3 months. The average price target is $10.50, with a high forecast of $12.00 and a low forecast of $9.00. The average price target represents a 140.83% upside from the last price of $4.36.

This chart shows the closing price for ANIX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Anixa Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/23/2023HC WainwrightBoost TargetBuy$11.00 ➝ $12.00Low
3/22/2023Chardan CapitalReiterated RatingBuy$8.00 ➝ $9.00Low
2/28/2023HC WainwrightReiterated RatingBuy$11.00Low
12/23/2022Chardan CapitalInitiated CoverageBuy$8.00Low
10/4/2021HC WainwrightReiterated RatingBuy$11.00High
8/31/2021HC WainwrightReiterated RatingBuy$11.00Medium
5/21/2021HC WainwrightReiterated RatingBuy$11.00Medium
4/19/2021HC WainwrightInitiated CoverageBuy$11.00High
4/12/2021HC WainwrightInitiated CoverageBuy$11.00High
2/15/2021AegisReiterated RatingBuyHigh
6/2/2020AegisReiterated RatingBuyMedium
3/23/2020AegisInitiated CoverageBuy$8.50High
12/30/2019B. RileyLower TargetBuy$11.25 ➝ $8.00High
9/13/2019B. RileySet TargetBuy$11.00Low
10/3/2018B. RileyReiterated RatingBuyHigh
10/3/2018B. RileyInitiated CoverageBuy$11.25N/A
(Data available from 3/26/2018 forward)

News Sentiment Rating

-0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
8/28/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/27/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
10/27/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
11/26/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/26/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/24/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Anixa Biosciences logo
Anixa Biosciences, Inc. is a biotechnology company, which engages in developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. It operates through the following segments: CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, Cancer Diagnostics, and Patent Licensing. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
Read More

Today's Range

Now: $4.36
Low: $4.11
High: $4.39

50 Day Range

MA: $4.38
Low: $3.86
High: $5.00

52 Week Range

Now: $4.36
Low: $2.50
High: $6.25

Volume

38,361 shs

Average Volume

78,537 shs

Market Capitalization

$134.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Anixa Biosciences?

The following Wall Street research analysts have issued stock ratings on Anixa Biosciences in the last year: Chardan Capital, and HC Wainwright.
View the latest analyst ratings for ANIX.

What is the current price target for Anixa Biosciences?

2 Wall Street analysts have set twelve-month price targets for Anixa Biosciences in the last year. Their average twelve-month price target is $10.50, suggesting a possible upside of 140.8%. HC Wainwright has the highest price target set, predicting ANIX will reach $12.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $9.00 for Anixa Biosciences in the next year.
View the latest price targets for ANIX.

What is the current consensus analyst rating for Anixa Biosciences?

Anixa Biosciences currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ANIX will outperform the market and that investors should add to their positions of Anixa Biosciences.
View the latest ratings for ANIX.

What other companies compete with Anixa Biosciences?

Other companies that are similar to Anixa Biosciences include Akebia Therapeutics, Y-mAbs Therapeutics, Incannex Healthcare, Nanobiotix and Inozyme Pharma. Learn More about companies similar to Anixa Biosciences.

How do I contact Anixa Biosciences' investor relations team?

Anixa Biosciences' physical mailing address is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118. The company's listed phone number is (408) 708-9808 and its investor relations email address is [email protected] The official website for Anixa Biosciences is www.anixa.com. Learn More about contacing Anixa Biosciences investor relations.